Mn Services Vermogensbeheer B.V. Has $6.64 Million Stock Holdings in The Clorox Company (NYSE:CLX)

Mn Services Vermogensbeheer B.V. reduced its position in The Clorox Company (NYSE:CLX - Free Report) by 7.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,109 shares of the company's stock after selling 3,700 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Clorox were worth $6,642,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Wedge Capital Management L L P NC boosted its stake in Clorox by 33.5% in the 1st quarter. Wedge Capital Management L L P NC now owns 28,510 shares of the company's stock valued at $4,198,000 after buying an additional 7,159 shares in the last quarter. California Public Employees Retirement System lifted its holdings in shares of Clorox by 1.3% during the fourth quarter. California Public Employees Retirement System now owns 565,810 shares of the company's stock valued at $91,893,000 after acquiring an additional 6,987 shares during the period. Rhumbline Advisers boosted its stake in shares of Clorox by 5.7% in the 1st quarter. Rhumbline Advisers now owns 273,462 shares of the company's stock valued at $40,267,000 after purchasing an additional 14,647 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of Clorox by 14.0% in the 4th quarter. Deutsche Bank AG now owns 654,198 shares of the company's stock worth $106,248,000 after purchasing an additional 80,189 shares during the last quarter. Finally, Willis Investment Counsel increased its position in shares of Clorox by 9.1% during the 1st quarter. Willis Investment Counsel now owns 202,678 shares of the company's stock worth $29,844,000 after purchasing an additional 16,893 shares in the last quarter. Institutional investors and hedge funds own 78.53% of the company's stock.

Analyst Upgrades and Downgrades

CLX has been the topic of a number of recent analyst reports. Evercore ISI set a $140.00 price target on shares of Clorox and gave the company an "underperform" rating in a research report on Tuesday, May 6th. Citigroup cut their target price on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating for the company in a research note on Monday, April 14th. Barclays decreased their price target on Clorox from $134.00 to $129.00 and set an "underweight" rating on the stock in a research report on Wednesday, May 7th. UBS Group cut their price objective on Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Finally, JPMorgan Chase & Co. reduced their price objective on Clorox from $151.00 to $144.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 6th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Clorox has an average rating of "Hold" and a consensus target price of $151.23.

Insider Activity at Clorox

In other news, Director Pierre R. Breber purchased 4,000 shares of Clorox stock in a transaction dated Wednesday, May 7th. The shares were bought at an average cost of $136.57 per share, with a total value of $546,280.00. Following the completion of the transaction, the director now directly owns 4,000 shares in the company, valued at $546,280. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.57% of the company's stock.

Clorox Trading Down 1.5%

Shares of CLX stock traded down $1.81 during trading hours on Tuesday, reaching $122.12. The company had a trading volume of 1,273,807 shares, compared to its average volume of 1,363,840. The Clorox Company has a 1-year low of $122.00 and a 1-year high of $171.37. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60. The firm has a market cap of $15.05 billion, a price-to-earnings ratio of 33.37, a P/E/G ratio of 2.62 and a beta of 0.54. The company has a 50 day moving average of $134.66 and a 200 day moving average of $147.91.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. The company's quarterly revenue was down 8.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.71 EPS. On average, equities research analysts anticipate that The Clorox Company will post 7.15 EPS for the current year.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.